Yahoo Finance

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Yahoo Finance

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Finanznachrichten

Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ...

Aktien»Nachrichten»RELAY THERAPEUTICS AKTIE»Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients ...
Mena FN

Relay Therapeutics Announces Efficacy Subset Analysis Of Zovegalisib (RLY-2608) + Fulvestrant In Breast Cancer Patients Pre-Treated With SERD Or With ESR1 Mutations At SABCS 2025

(MENAFN- GlobeNewsWire - Nasdaq) Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and median PFS in 2L patients Subset analyses show broad ...